null

null

null

null

null

null

null

null

null

Pre-revenue clinical-stage biotech; minimal long-term debt, primarily equity-funded via ATM and follow-on offerings; low leverage ratio <0.5x

Minimal direct debt sensitivity; rising rates increase cost of future equity dilution and reduce NPV of distant cash flows, compressing valuation multiples

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Lentiviral vector manufacturing (single-source CMOs like Oxford Biomedica) and specialty T-cell apheresis collection networks concentrated in US/EU

Revenues currently near zero commercial stage; GBP/USD and EUR/USD exposure on UK-domiciled R&D spend; limited sovereign currency devaluation risk on revenue side

Operations primarily UK (London HQ) and US; EU clinical sites; GBP and EUR operational exposure but no meaningful revenue FX risk yet

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; Oxford Biomedica historically sole lentiviral vector manufacturer, representing non-substitutable >30% operational input; switching would delay programs 18-24 months

Biopharmaceutical drug developer; cell therapy (CAR-T) manufacturer and commercializer; not cloud-dependent for core operations

Cloud disruption impact moderate; clinical data management and bioinformatics pipelines would face 3-6 month disruption but core wet-lab manufacturing unaffected

Low API coupling risk; primary dependencies are on specialized biomanufacturing processes and proprietary vector technology, not software APIs

Not applicable; revenue model is pharmaceutical drug sales and licensing, not an investment contract; Howey Test risk negligible

Very High

Moderate GDPR exposure via EU patient clinical trial data; CCPA limited given minimal US consumer data; compliance frameworks standard for clinical-stage pharma

Low antitrust risk; niche CAR-T oncology market, no dominant market position; faces competition from Novartis, BMS, Kite reducing any monopoly concern

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional/milestone-based; obe-cel approved 2024 (AUCATZYL); early commercial revenues transactional per-infusion, no subscription component

Per-patient infusion pricing (~$400K-$500K per treatment anticipated), milestone and royalty potential from partnerships; one-time high-value transactions

Single-course curative-intent therapy pricing; reimbursement pressure from payers is primary stress point; net pricing dependent on outcomes-based contracts

Moderate-high; differentiated CAR-T with potential functional cure positioning supports premium pricing, but payer pushback and competition cap upside; rated 6/10

Long-term target 70-80% gross margin at scale; near-term manufacturing costs elevated at CMO scale, likely 30-50% gross margin in early commercial phase

Not applicable; one-time curative treatment eliminates repeat-purchase model; no free-rider or churn dynamic relevant

Sublinear at scale; manufacturing scale-up through CMO partnerships limits headcount linearity; commercial team headcount grows but slower than revenue at maturity

Marginal cost driven by COGS per batch (CMO manufacturing), not headcount; doubling revenue requires ~50-70% increase in manufacturing capacity, not headcount doubling

Not applicable; Autolus operates no franchise network

At 10x scale, CAC per treatment center onboarding amortizes favorably; key bottleneck is qualified treatment center capacity and apheresis slot availability

Minimal network effects; clinical outcome data accumulation creates mild data moat but no traditional demand-side network effect; durability rated low

-48.5% Return on Assets (Negative equity)

Tier 2 recession resistant; oncology treatments are non-discretionary for diagnosed patients; reimbursement risk from payer cost-cutting is primary recession vulnerability

Oncology treatment centers and hospital systems (B2B) administering obe-cel to adult B-ALL patients; ~100 certified CAR-T centers in US

NHS and EU hospital formularies for future ex-US commercial rollout; academic medical centers driving initial adoption and clinical evidence generation

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

25.3% CapEx / Revenue (High-CapEx Infrastructure)

0001730463

AUTL